Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival

Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival

Source: 
Fierce Biotech
snippet: 

Eli Lilly has turned over the cards on its $1.1 billion bid to challenge Sanofi and Regeneron’s Dupixent for the atopic dermatitis market. Analysts at Jefferies called the data compelling, although a hoped-for point of differentiation over the blockbuster incumbent has weakened.